Wednesday, March 22, 2017 8:01:53 AM
Marc Oczachowski, Chief Executive Officer of EDAP TMS, added: "There is a growing number of patients who failed their radiotherapy treatment and require a secondary option; this large and growing market opportunity is the result of an as-yet unmet medical need. Pr. Sébastien Crouzet's clinical publication reconfirms that EDAP's Ablatherm HIFU technology offers a valuable answer to this need and is well positioned to serve this growing population with minimal competition."
http://ih.advfn.com/p.php?pid=nmona&article=74155612
Now if some more institutional investors would show up.
"Perfection is not attainable, but if we chase perfection we can catch
excellence." Vince Lombardi
Do your research! Play the TA. All posts are my opinion.
Recent EDAP News
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
